Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen

A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)

Mounzer, Karam
Slim, Jihad
Ramgopal, Moti
Hedgcock, Malcolm
Bloch, Mark
Santana, Jorge
Mendes, Ines
Guo, Ying
Arora, Priyanka
Montezuma-Rusca, Jairo M
Sklar, Peter
Baeten, Jared M
Segal-Maurer, Sorana

The Jonathon Lax Immune Disorders Treatment Center, Philadelphia FIGHT, Philadelphia, Pennsylvania, USA
New York Medical College, Valhalla, New York, USA
Midway Immunology and Research Center, Fort Pierce, Florida, USA
Spectrum Health, Vancouver, British Columbia, Canada
Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia
School of Medicine, University of Puerto Rico, San Juan, Puerto Rico
Patient Safety, Gilead Sciences, Inc., Foster City, California, USA
Biostatistics, Gilead Sciences, Inc., Foster City, California, USA
Clinical Pharmacology, Gilead Sciences, Inc., Foster City, California, USA
Clinical Development, Gilead Sciences, Inc., Foster City, California, USA
Clinical Development, Gilead Sciences, Inc., Foster City, California, USA
Clinical Development, Gilead Sciences, Inc., Foster City, California, USA
Medical Affairs, Gilead Sciences, Inc., Foster City, California, USA

Affiliation at the time of study: New York-Presbyterian Queens, Flushing, New York, USA.

Correspondence: K. Mounzer, Jonathon Lax Immune Disorders Treatment Center, Philadelphia FIGHT, 1233 Locust Street, Philadelphia, PA 19107 ([email protected]).

Received June 28, 2024

Revised November 26, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].

Clinical Infectious Diseases 80(4):p 881-888, April 15, 2025. | DOI: 10.1093/cid/ciae522